Ceftazidime/clindamycin versus tobramycin/clindamycin treatment intra-abdominal infections order efficacy toxicity ceftazidime substitute aminoglycosides treatment intra-abdominal sepsis prospective trial Ninety-four patients trauma ceftazidime/clindamycin CAZ/C tobramycin/clindamycin T/C CAZ gm gm hours dosage peak mg/L mg/L concentrations Age sex baseline serum creatinine etiology infection comparable groups Clinical cure similar culture-positive culture-negative patients CAZ/C vs clinical cure rate T/C culture positive culture negative patients Pathogenic organisms CAZ/C T/C patients Nephrotoxicity Nephrotoxicity ototoxicity none CAZ/C patients T/C patients CAZ/C bacteria patients significant difference clinical response culture-positive patients findings lack toxicity CAZ/C effective alternative treatment IAI 